AUS
NZ
UK
CA
USA
IND
Highlights
- Aclaris Therapeutics holds 98.3% institutional share ownership.
- Gross revenue reported by Aclaris is $27.08 million.
- Theratechnologies exhibits a lower Price/Sales ratio than Aclaris.
Within the biotechnology sector, companies like Aclaris Therapeutics and Theratechnologies play pivotal roles in developing medical treatments and therapies. This sector is characterized by intensive research and development activities aimed at addressing various health challenges.
Insider and Institutional Ownership
Aclaris Therapeutics (NASDAQ:ACRS) has a substantial portion of its shares, 98.3%, held by institutional entities. Additionally, insiders own 6.4% of the company's shares. High levels of institutional ownership typically indicate strong confidence from large financial institutions in the company's governance and strategic direction.
Financial Performance Comparison
A comparative analysis of Aclaris Therapeutics and Theratechnologies reveals significant differences in their financial metrics. Aclaris reports a gross revenue of $27.08 million, while Theratechnologies achieves a higher gross revenue of $84.32 million. The Price/Sales ratio for Aclaris stands at 8.60, contrasting with Theratechnologies' ratio of 0.88. This metric reflects the valuation placed on each dollar of sales generated by the companies.
Earnings Overview
Examining net income, Aclaris Therapeutics has reported a loss of $88.48 million, resulting in an earnings per share (EPS) of ($0.52). In comparison, Theratechnologies has a net loss of $23.96 million and an EPS of ($0.10). The Price/Earnings ratio for Aclaris is -6.27, while Theratechnologies has a ratio of -16.20, indicating different levels of profitability challenges faced by both entities.
Market Valuation Insights
The differing Price/Sales ratios between Aclaris Therapeutics and Theratechnologies suggest varying market valuations relative to their sales. Aclaris's higher ratio may indicate a higher market valuation per dollar of sales, whereas Theratechnologies' lower ratio points to a more modest valuation in comparison to its revenue.
Shareholding Structure
The shareholding distribution in Aclaris Therapeutics shows a dominant institutional presence, which is often associated with enhanced stability and strategic support. The insider ownership, though a smaller percentage, reflects a significant stake by those directly involved in the company's operations and decision-making processes.
Revenue Generation
The revenue figures highlight the operational scale of both companies. Theratechnologies, with a gross revenue of $84.32 million, operates on a larger scale compared to Aclaris Therapeutics' $27.08 million. This difference may be attributed to a broader market reach or a more extensive range of products and services offered by Theratechnologies.
Earnings Per Share Analysis
The earnings per share metric provides insight into the financial performance of the companies on a per-share basis. Aclaris Therapeutics' EPS of ($0.52) indicates a greater loss per share compared to Theratechnologies' EPS of ($0.10). This suggests differing operational efficiencies and financial health between the two companies.
Price Ratios Interpretation
Price/Sales and Price/Earnings ratios serve as indicators of how the market values the companies in relation to their sales and earnings. Aclaris Therapeutics' higher Price/Sales ratio compared to Theratechnologies may reflect higher market expectations based on sales performance, whereas the differing Price/Earnings ratios highlight varying investor sentiments regarding each company's profitability.
